CAMBRIDGE, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Idenix
Pharmaceuticals, Inc. (NASDAQ:IDIX), a biopharmaceutical company
engaged in the discovery and development of drugs for the treatment
of human viral and other infectious diseases, today reported
unaudited financial results for the third quarter and nine months
ended September 30, 2008. At September 30, 2008, Idenix's cash,
cash equivalents and marketable securities totaled approximately
$60.1 million. 2008 Year-to-Date Business Highlights -- Idenix
completed its phase I/II study of IDX899, a non-nucleoside reverse
transcriptase inhibitor (NNRTI) being developed for the treatment
of HIV-1, which demonstrated potent antiviral activity at all doses
tested. Patients receiving once-daily IDX899 achieved a mean plasma
viral load reduction of approximately 1.8 log10 after seven days of
treatment in each of the 800 mg, 400 mg, 200 mg and 100 mg dosing
cohorts (n=8 per treatment group). Patients receiving placebo (n=8)
had a mean viral load increase of 0.10 log10 over the same
treatment period. The safety profile of IDX899 observed during this
study was comparable to placebo, with no serious adverse events
reported and no pattern of adverse events or laboratory
abnormalities observed on treatment. Additionally, no patients who
received treatment discontinued the study. -- Idenix also continued
to advance its HCV discovery and development programs, successfully
completing a first-in-man phase I study of IDX184, a nucleotide
prodrug candidate, and initiating the IND-enabling preclinical
studies for IDX375, a non-nucleoside polymerase inhibitor, and
IDX136 and IDX316, macrocyclic protease inhibitor drug candidates.
"As we advance our HCV and HIV discovery and development programs,
we remain excited about the opportunities ahead for Idenix," said
Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer
of Idenix. For the third quarter ended September 30, 2008, Idenix
reported total revenues of $2.1 million, compared with total
revenues of $10.9 million in the third quarter of 2007. The
decrease was primarily due to a decline of $7.4 million in
reimbursements of research and development costs from Novartis
Pharma AG, Idenix's collaboration partner. Idenix reported a net
loss of $16.9 million, or a loss of $0.30 per basic and diluted
share, for the third quarter ended September 30, 2008, compared to
a net loss of $30.5 million, or a loss of $0.54 per basic and
diluted share for the third quarter ended September 30, 2007. For
the nine months ended September 30, 2008, Idenix reported total
revenues of $5.8 million, compared with total revenues of $55.4
million for the nine months ended September 30, 2007. The majority
of the decrease was due to $30.4 million in lower reimbursements of
research and development costs from Novartis, a decrease of $10.0
million due to lower milestone revenue in 2008 as compared to 2007
and $9.3 million due to lower license fee revenue. The company
reported a net loss of $56.3 million, or a loss of $1.00 per basic
and diluted share for the nine months ended September 30, 2008,
compared with $65.0 million, or a loss of $1.16 per basic and
diluted share for the nine months ended September 30, 2007. 2008
Financial Guidance Idenix currently expects to end 2008 with
approximately $45 to $50 million of cash, cash equivalents and
marketable securities, assuming no milestone payments, license
fees, reimbursement for development programs, and assuming no
financing activities during the remainder of 2008. Conference Call
and Webcast Information Idenix will hold a conference call today at
4:30 p.m. ET. To access the call please dial (800) 471-3635
U.S./Canada or (706) 758-9475 International and enter passcode
69258196. To listen to a live webcast of the call, go to "Calendar
of Events" in the Idenix Investor Center at http://www.idenix.com/.
Please log in approximately 10 minutes before the call to ensure a
timely connection. A replay of the conference call and webcast will
be available until November 13, 2008. To access the replay, please
dial (800) 642-1687 U.S./Canada or (706) 645-9291 International and
enter the passcode 69258196. About Idenix Idenix Pharmaceuticals,
Inc., headquartered in Cambridge, Massachusetts, is a
biopharmaceutical company engaged in the discovery and development
of drugs for the treatment of human viral and other infectious
diseases. Idenix's current focus is on the treatment of infections
caused by hepatitis C virus and HIV. For further information about
Idenix, please refer to http://www.idenix.com/. Forward-looking
Statements This press release contains "forward-looking statements"
within the meaning of The Private Securities Litigation Reform Act
of 1995. Such forward- looking statements can be identified by the
use of forward-looking terminology such as "expect," "plans,"
"anticipates," "will," or similar expressions, or by express or
implied statements with respect to the company's clinical
development programs or commercialization activities in HIV or
hepatitis C, or any potential pipeline candidates and expectations
with respect to additional milestone payments, future royalty
payments and cash balances at the end of 2008. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results to be materially different
from any future results, performance or achievements expressed or
implied by such statements. There can be no guarantees that
historical sales of Tyzeka(R)/Sebivo(R) (telbivudine) will in any
way suggest future royalty payments or royalty rates owed to the
company, or that the company will advance any clinical product
candidate or other component of its potential pipeline to the
clinic, to the regulatory process or to commercialization. In
particular, management's expectations could be affected by
unexpected regulatory actions or delays; uncertainties relating to,
or unsuccessful results of, clinical trials, including additional
data relating to the ongoing clinical trials evaluating its product
candidates; the company's ability to obtain additional funding
required to conduct its research, development and commercialization
activities; the company's dependence on its collaboration with
Novartis Pharma AG; changes in the company's business plan or
objectives; the ability of the company to attract and retain
qualified personnel; competition in general; and the company's
ability to obtain, maintain and enforce patent and other
intellectual property protection for its product candidates and its
discoveries. These and other risks which may impact management's
expectations are described in greater detail under the caption
"Risk Factors" in the company's quarterly report on Form 10-Q for
the quarter ended June 30, 2008 as filed with the Securities and
Exchange Commission (SEC) and other filings that the company makes
with the SEC. All forward-looking statements reflect the company's
expectations only as of the date of this release and should not be
relied upon as reflecting the company's views, expectations or
beliefs at any date subsequent to the date of this release. Idenix
anticipates that subsequent events and developments may cause these
views, expectations and beliefs to change. However, while Idenix
may elect to update these forward-looking statements at some point
in the future, it specifically disclaims any obligation to do so.
Idenix Pharmaceuticals' Contacts: Media: Teri Dahlman (617)
995-9905 Investors: Amy Sullivan (617) 995-9838 IDENIX
PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS (IN THOUSANDS, EXCEPT PER SHARE DATA) (UNAUDITED) Three
Months Ended Nine Months Ended September 30, September 30, 2008
2007 2008 2007 Revenues: Collaboration revenue - related party
$2,089 $9,153 $5,568 $52,178 Other revenue 56 1,735 212 3,248 Total
revenues 2,145 10,888 5,780 55,426 Operating expenses (1): Cost of
sales 456 277 1,266 514 Research and development 12,933 18,421
41,938 65,545 Selling, general and administrative 6,457 18,393
21,428 54,070 Restructuring and impairment charges ----- 6,439 297
6,439 Total operating expenses 19,846 43,530 64,929 126,568 Loss
from operations (17,701) (32,642) (59,149) (71,142) Investment
income and other income, net 137 1,718 1,562 5,498 Loss before
income taxes (17,564) (30,924) (57,587) (65,644) Income tax benefit
673 375 1,330 624 Net loss $(16,891) $(30,549) $(56,257) $(65,020)
Basic and diluted net loss per share: ($0.30) ($0.54) ($1.00)
($1.16) Shares used in calculation of basic and diluted net loss
per share: 56,454 56,189 56,363 56,162 (1) Stock-based compensation
expenses included in operating expenses amounted to approximately:
Research and development $439 $553 $1,565 $2,444 Selling, general
and administrative 851 1,326 2,607 3,859 Restructuring and
impairment charges ----- 968 ----- 968 IDENIX PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS) (UNAUDITED)
September 30, December 31, 2008 2007 ASSETS Cash and cash
equivalents $45,695 $48,260 Marketable securities 6,935 39,862
Receivables from related party 984 11,196 Other current assets
3,218 4,401 Total current assets 56,832 103,719 Intangible asset,
net 12,677 13,548 Property and equipment, net 14,054 15,460
Marketable securities, non-current 7,461 23,882 Other assets 4,337
3,931 Total assets $95,361 $160,540 LIABILITIES AND STOCKHOLDERS'
EQUITY Accounts payable and accrued expenses $12,165 $21,809
Deferred revenue, related party 5,764 8,372 Other current
liabilities 667 553 Total current liabilities 18,596 30,734
Long-term obligations 17,538 19,107 Deferred revenue, related
party, net of current portion 36,028 41,861 Total liabilities
72,162 91,702 Stockholders' equity 23,199 68,838 Total liabilities
and stockholders' equity $95,361 $160,540 DATASOURCE: Idenix
Pharmaceuticals, Inc. CONTACT: Media, Teri Dahlman,
+1-617-995-9905, or Investors, Amy Sullivan, +1-617-995-9838 Web
site: http://www.idenix.com/
Copyright
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024